About Us >>



Management team



Taivex Therapeutics Inc., founded in 2010, is focus on the development of "Novel" , "Niche" and "Targeting" anti-cancer drugs.

Taivex has proprietary technology platforms to identify compounds that inhibit the Hec1-Nek2 interactions. Hec1 was found to be over-expressed in many cancer cells, and the phosphorylation of Hec1 by Nek2 is critical for proper mitotic progress and chromosome segregation. Interruption of Hec1-Nek2 interaction results in mitotic defects, which lead to cell death. Hec1-Nek2 interactions regulate key events in the progression of human tumors, and therefore are attractive molecule targets for the development of new anti-cancer drugs.